Serhat Toprak

Serhat Toprak

Auto-generated profile, based on publicly available information

Serhat Toprak

Department of Pathology, Faculty of Medicine, Inonu University, Malatya, Turkiye

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2019 in Journal of Obstetrics and Gynaecology
Verified
Journal Article
Closed access
EYErcan Yilmaz
Ercan Yilmaz
Rauf MelekogluRauf Melekoglu
Rauf Melekoglu
CTCagatay Taskapan
Cagatay Taskapan
FBFatma Olmez Budak
Fatma Olmez Budak
STSerhat Toprak
Serhat Toprak
The aim of this study was to investigate the serum levels of the A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) 5 and 8 in patients diagnosed with endometrial cancer. Our study included 41 patients diagnosed with endometrial cancer. The control group consisted of 41 patients diagnosed with benign endometrial pathology. The serum samples were centrifuged and stored at –80 °C. The serum levels of ADAMTS were significantly higher (p<.001), whereas the levels of ADAMTS 8 were significantly lower in patients diagnosed with cancer (p<.001). In addition to the presence of known factors in the aetiology of endometrial cancer, the effect of inflammatory factors and some new proteins has centred on the causes of tumourigenesis in recent years. In this sense, these proteins, called the ADAMTS, are the source of new studies.

1 December 2024 in Cancer Biomarkers
Verified
Journal Article
Open access
SÜSongül Ünüvar
Songül Ünüvar
RMRauf Melekoğlu
Rauf Melekoğlu
HYHande Yüce
Hande Yüce
NÇNesibe Zeyveli Çelik
Nesibe Zeyveli Çelik
EOEzgi Bulut Okumuş
Ezgi Bulut Okumuş
SSSüleyman Sandal
Süleyman Sandal
Background: Endometrial cancer (EC) is the fourth most common gynecologic malignancy among women. Histopathologic examination is considered gold-standard for diagnosis of EC. However, these examinations sometimes not be useful in distinguishing early stage types of EC. Objectıves: The current study aimed to investigate the clinicopathological significance of Lipocalin-2 (LCN2), matrix metalloproteinase-9 (MMP9), and ferritin in tumor progression. Methods: A total of 98 patients (55 women newly diagnosed with early-stage endometrial cancer [study group] and 43 women with benign endometrial pathologies [control group]) were enrolled. Results: There was a significant difference between diagnosis (p < 0.001), surgical procedure (p < 0.001), pathology (p = 0.002), stage (p < 0.001), lymphovascular invasion (LVI) (p = 0.002), myometrial invasion (p < 0.001), and staining intensity (p < 0.001), MMP9 (p = 0.023), LCN2 (p < 0.001), glucocorticoid (GC) (p = 0.048), tumor necrosis factor-alpha (TNF-α) (p = 0.044), menopause duration (p = 0.001), body weight (p < 0.001), and body mass index (BMI) (p < 0.001) were found to be higher, and ferritin levels (p = 0.047) were lower in the endometrial adenocarcinoma group compared to the benign endometrial pathologies. Conclusıon: LCN2, MMP9, and ferritin are practical markers in early cases of endometrial cancer. Serum LCN2 and MMP9 levels may be good clinical tools for the auxiliary diagnosis of early-stage endometrial cancer. Ferritin was also significantly sensitive. Therefore, detecting these markers together may be more beneficial for cancer diagnosis.

30 July 2024 in Otolaryngology Case Reports
Verified
Journal Article
Open access
ESEsma Hande Sözübatmaz
Esma Hande Sözübatmaz
MAMehmet Aslan
Mehmet Aslan
STSerhat Toprak
Serhat Toprak

1 April 2022 in Journal of Surgery and Medicine
Verified
Journal Article
Open access
PDF file
ABAyse Gulcin Bastemur
Ayse Gulcin Bastemur
BÇBarış Çıplak
Barış Çıplak
Rauf MelekogluRauf Melekoglu
Rauf Melekoglu
STSerhat Toprak
Serhat Toprak
CKCemalettin Koç
Cemalettin Koç
EYErcan Yilmaz
Ercan Yilmaz
Background/Aim: Ovarian cancer is the second most common gynecologic malignancy worldwide and is the deadliest among gynecological cancers. It is important that this cancer, which is usually diagnosed in advanced stages, is referred to a gynecologist oncologist without delay. An ideal screening method does not yet exist. Although CA 125 is still the most used tumor marker, it cannot detect early-stage ovarian cancer. Also, CA 125 is not specific for ovarian malignancy. Therefore, new serum markers, such as HE4, and more complex algorithms, like ROMA and RMI, have emerged. Here we evaluate the preoperative potential of patients with adnexal mass to have a malignant or benign mass with morphological index, CA 125, HE4, RMI, and ROMA tests. Methods: This study is a prospective cohort study. A power analysis was done before starting the study. The sample size was at least 80 when the Type I error was set at 0.05, and the confidence interval was 95%. We included into the study 84 patients admitted to our clinic because of pelvic mass and underwent operation between March 2016 and October 2018. To homogenize the benign and malignant groups, 42 patients were collected from each group. CA 125 and HE4 levels of the samples were studied by the electrochemiluminescence method. ROMA and RMI values were calculated, and the data were entered into SPSS. Data were analyzed using SPSS 22.0 statistical package program. Results: Each of the CA 125 (P = 0.002), HE4 (P < 0.001), morphological index (P < 0.001), ROMA (P < 0.001), and RMI (P < 0.001) tests has been successful in differentiating malignant masses from benign masses. In the malignant-benign differentiation of adnexal masses preoperatively, CA 125 was the test with the lowest sensitivity, and RMI had the highest sensitivity. However, in the ROC analysis, the morphological index has a higher area under the curve. Conclusion: Although CA 125 is still the most frequently used marker in the preoperative evaluation of adnexal masses, it has low specificity and sensitivity, especially in premenopausal patients. The use of new tumor markers (e.g., HE4) and other algorithms (e.g., ROMA and RMI) is supported by our findings and the literature. However, here we show that an expert ultrasonographic evaluation with morphological index alone could be effective.

20 June 2022
Verified
Book
Closed access
PDF file
MOMelike Ordu
Melike Ordu
MNMelike Nalbant
Melike Nalbant
STSerhat Toprak
Serhat Toprak
EHEzgi Hacıhasanoğlu
Ezgi Hacıhasanoğlu
EAEsra Çobankent Aytekin
Esra Çobankent Aytekin
ODOsman Demirhan
Osman Demirhan
Onkoloji alanındaki tüm dünyanın yakın takip ettiği bilimsel gelişmeler ışığında günümüzde artık sistemik kemoterapi gibi konvansiyonel tedaviler yerlerini büyük ölçüde immünoterapi, moleküler hedefli ilaçlar ve gen tedavilerine bırakmaya başlamıştır. Bu tedavi stratejilerinin geliştirilmesi, yeni ilaçların keşifleri ve mevcut ilaçlara karşı gelişen direnç mekanizmalarının anlaşılması ve tümörlerin detaylı kimliklendirilmelerinin önemi tartışılmaz bir gerçek ve gereklilik haline gelmiştir. Moleküler ve genetik temelli çalışmalar bize bu imkanları sağlama konusunda çok önemli katkılar sağlamaktadır.